Scholars Central

Conference abstractPublished 20 Nov 2017

EGFR blockade reverses chemo resistance in human ovarian carcinoma cells

Authors: Arash Poursheikhani, Majid Momeny, Ghazaleh Zarrinrad, Hassan Yousefi, Fatemeh Esmaili, Javad Tavakkoli Bazzaz, Seyed H Ghaffari

Tehran University of Medical Sciences, Iran

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Epithelial ovarian cancer (EOC) is the most fatal gynecological malignancy worldwide. Despite improvements in cytoreductive surgery and primary chemotherapy, the majority of patients with advanced disease relapse and exhibit crossresistance to chemotherapeutic drugs. Recurrent EOC is currently an incurable disease and overcoming drug resistance is the key to successful treatment. There is therefore an urgent need for effective treatments to circumvent chemo resistance in the EOC. In this report, we showed that treatment of the EOC cells with a wide range of chemotherapeutics including cisplatin, carboplatin, gemcitabine, vincristine and doxorubicin as well as monoclonal antibodies such as bevacizumab induces EGFR ligands such as heparin-binding epidermal growth factor (HB-EGF). Amphiregulin (AREG) and Epiregulin (EREG) is a phenomenon which was abrogated when the cells were pre-treated with the anti-EGFR mAb cetuximab. Moreover, these findings show that pre-treatment of the cells with gefitinib (EGFR small molecule inhibitor), Buparlisib (a pan-PI3K inhibitor), Trametinib (a MEK1/2-specific inhibitor) and bay 11-7082 (inhibitor of NF- Ã?ºB) hindered chemotherapy-mediated EGF-like growth factors induction and synergistically re-sensitized the chemo resistant cells to cisplatin. Altogether, these data suggest that EGFR mediates stress-induced expression of its ligands and thereby chemo resistance in the EOC cells via activation of its down-stream pathways such as ERK1/2, AKT and NF-Ã?ºB.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Arash Poursheikhani”
  • BylineArticles whose byline prints “Majid Momeny”
  • BylineArticles whose byline prints “Ghazaleh Zarrinrad”
  • BylineArticles whose byline prints “Hassan Yousefi”
  • BylineArticles whose byline prints “Fatemeh Esmaili”
  • BylineArticles whose byline prints “Javad Tavakkoli Bazzaz”
  • BylineArticles whose byline prints “Seyed H Ghaffari”